Keating Gillian M, Robinson Dean M
Wolters Kluwer Health | Adis, Auckland, New Zealand.
Drugs. 2007;67(7):1077-95. doi: 10.2165/00003495-200767070-00008.
Quetiapine (Seroquel) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life (HR-QOL). Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.
喹硫平（思瑞康）是美国唯一获批可作为单一疗法用于双相躁狂和抑郁治疗的非典型抗精神病药物，具有潜在的依从性优势。每日口服300毫克喹硫平单一疗法对治疗I型或II型双相抑郁患者有效。喹硫平可使抑郁和焦虑症状迅速且持续改善，同时还能改善健康相关生活质量（HR-QOL）。喹硫平在双相抑郁中通常耐受性良好，且与治疗引发躁狂的风险增加无关。因此，尽管目前缺乏来自活性对照试验的数据，但喹硫平单一疗法应被视为双相抑郁急性治疗的一线选择。
